Chiranjib Chakraborty, PhD

Professor Chiranjib Chakraborty

Present Position: JC Bose Chair Professor

Department of Biotechnology, School of Life Science & Biotechnology

E-mail: chiranjib.chakravartty@adamasuniversity.ac.in

Education:

  • Ph.D. (2001): (Vidyasagar University), Midnapore, West Bengal, India. (PhD research work has been carried out in Marine Aquarium and Research Centre (ZSI), WB, India)
  • M.Sc. (1995): (Kanpur University), Kanpur, U.P., India Presently, (Chhatrapati Shahu Ji Maharaj University, Kanpur)
  • B.Sc. (Hons.) (1993): The (University of Burdwan, Burdwan, India).

Research Key Areas:

  • Research interest: Infectious diseases, Global Health, Mutation, AI, Bioinformatics/Immunoinformatic

Research Highlights:

  • Per-paper citation is 76.24, with a per-paper impact factor of 10.12
  • SCI/SCIE indexed publications: 373
  • Book chapters: 11
  • Google Scholar: h-index 75, i10 index 256, Citations 28441
  • Scopus: h-index 64, Citations 23282
  • Average impact factor: 10.12 (cumulative: 3775.81)
  • Patents granted: 23 (19 international, 4 national); 15 applications pending
  • Technologies developed: 33
  • First author publications: 186; Corresponding author: 227
  • PhD students guided: 4 (3 completed)
  • Keynote Speech: 7; Invited talks: 35
  • Research awards: 15

 

Google Scholar ID: 3m8rwpUAAAAJ

Scopus ID: 56219079200

Orcid ID: 0000-0002-3958-239X

Web of Science Researcher ID: AAV-1132-2021

Experience:

  • More than 30 years in Scientific Research and Teaching experience in India and aboard.
  • Total research experience: 30 Years [including industrial R&D (Industrial Research & Development) experience: 4 years]
  • Total teaching experience: 23 Years

 

Within India

 

  1. Adamas University, Kolkata (Period: October, 2018- Till Date)
  • JC Bose Chair Professor, Department of Biotechnology, School of Life Science and Biotechnology, Adamas University, Barrackpore –Barasat Rd, Kolkata, India (July 2025- till date) (Current Position)

(Note: The Chair is named after the pioneer Indian scientist  and academician Sir Jagadish Chandra Bose (JC Bose))

  • Director (Founder Director), Centre of Excellence for Advanced Medical Bioinformatics and Artificial Intelligence (October, 2025- Till date) (Current Position)
  • Chair Professor, Department of Biotechnology, School of Life Science and Biotechnology, Adamas University, Barrackpore –Barasat Rd, Kolkata, India (July, 2024- July, 2025)
  • Professor, Department of Biotechnology, School of Life Science and Biotechnology, Adamas University, Barrackpore –Barasat Rd, Kolkata, India (October, 2018- June, 2024)
  1. Galgotias University, Greater Noida (Period: May, 2012- September,2018)
  • Professor, Department of Biochemistry, Galgotias University, Greater Noida, India (May, 2012- September,2018)
  1. Indian Statistical Institute, Kolkata (Visiting Position)
  • Visiting Scientist, Machine Intelligence Unit, Indian Statistical Institute, Kolkata, India (March 12, 2014 to March 21, 2014)
  • Visiting Scientist, Machine Intelligence Unit, Indian Statistical Institute, Kolkata, India (December 02, -2011 to December 30,2011)
  1. VIT University, Vellore (Period: April, 2010- April, 2012)
  • Associate Professor, Medical Biotechnology Division, School of Bio-Sciences and Technology, VIT University, Vellore, India (April, 2010- April, 2012)
  1. College of Engineering and Technology (IILM Academy of Higher Learning), Greater Noida (Period: July,2005-April,2010)
  • Associate Professor Dept. of Biotechnology, College of Engineering and Technology (IILM) (Under GB Technical University, UP) Greater Noida, UP. (Jan,2009-April,2010)
  • Assistant Professor, Dept. of Biotechnology, College of Engineering and Technology (IILM) (GB Technical University, UP) Greater Noida, UP. (July,2005 –Dec, 2008)

 

  1. Institute of Applied Medicines and Research (IAMR) (Under CCS University, Meerut, UP), Ghaziabad, UP, India
  • Assistant Professor, Dept. of Biotechnology, Institute of Applied Medicines and Research (IAMR) (June,2004 –June, 2005)

 

  1. Sr. Scientist (Critical care medicine and biotechnology), Glenmark Laboratories, Mumbai, India (May,2002 – June,2004)

 

  1. Research Scientist, Macleods Pharmaceuticals Ltd, Mumbai, India (August,2000 – April,2002)

 

  1. Lecturer (Ad-Hoc), Burdwan Raj College, Burdwan, West Bengal, India (April,1999 – July,2000)

 

  1. Visiting Research Fellow, Department of Life Science and Biotechnology, Jadavpur University, Calcutta, (October-November,1999)
  2. Research Scholar, Marine Aquarium & Research Center (Zoological Survey of India), Digha, West Bengal (December,1995 – April,1999)

 

Outside India

  1. Research Director in Bioinformatics (as Advisory Professor), Institute for Skeletal Aging (ISA), Hallym University, College of Medicine, Chuncheon, Gangwon-do, South Korea (QS World University Ranking 571-580 in the year 2023)(December 2014 to till date) (Current Position)
  2. Visiting Professor, Institute for Skeletal Aging & Orthopedic Surgery, Hallym University, College of Medicine, Chucheon, Gangwondo, South Korea (December 2018-January 2019)
  3. Visiting Professor, Institute for Skeletal Aging & Orthopedic Surgery, Hallym University, College of Medicine, Chucheon, Gangwondo, South Korea (May2015-June 2015)
  4. Visiting Professor, Institute for Skeletal Aging & Orthopedic Surgery, Hallym University, College of Medicine, Chucheon, Gangwondo, South Korea (November2013-December, 2013)
  5. Visiting Research Fellow, Department of Computer Sciences, Hong Kong Baptist University, Kowloon Tong, Hong Kong (November, 2014-December,2014)
  6. Sr. Visiting Fellow, Institute of Animal Science and Veterinary Medicine, Chinese Academy of Agricultural Sciences, Beijing 100193, China (October-December, 2009)
  7. Visiting Research Professor, Dept. of Marine Biotechnology and Resources, National Sun Yat-sen University; Kaohisung; Taiwan (July,2006 – January, 2007)
  8. Post Doctoral Fellow, University of Massachusetts, Dartmouth, USA. ( 2002-2003)

 

Administrative Experience

Adamas University, Kolkata (Period: October, 2018- Till Date)

  • Vice-Chancellor (Acting), Adamas University, Barrackpore –Barasat Rd, Kolkata, India (for a day on 3rd October 2019)
  • Dean, School of Life Science and Biotechnology, Adamas University, Barrackpore –Barasat Rd, Kolkata, India (March, 2019- December, 2019)
  • Director, Innovation Centre, Adamas University, Barrackpore –Barasat Rd, Kolkata, India (October, 2018- Till Date)

Galgotias University, Greater Noida (Period: May, 2012- September,2018)

  • Research Director, Galgotias University, Greater Noida, India (March, 2018- September,2018)

Applied Medicines and Research (IAMR) (Under CCS University, Meerut, UP), Ghaziabad, UP, India ( July,2004 –June, 2005)

  • Head, Dept. of Biotechnology, Institute of Applied Medicines and Research (IAMR) (Under CCS University, Meerut, UP), Ghaziabad, UP, India ( July,2004 –June, 2005)

Research Publication (s):

SELECTED SIGNIFICANT PUBLICATIONS (SCI/SCIE/ ESCI PUBLICATIONS)

 

  1. Chakraborty C*, Sharma A, Sharma G, Doss CG, Lee SS (2017) Therapeutic miRNA and siRNA: moving from bench to clinic as next generation medicine. Molecular Therapy-Nucleic Acids 8: 132–143. IF: 6.5 (Journal Category: Q1) (*First and Corresponding Author)

[https://pubmed.ncbi.nlm.nih.gov/28918016/] (Citation index: 936)

[Molecular Therapy – Nucleic Acids is an official journal of the American Society of Gene & Cell Therapy and a Cell Press Journal]

  1. 2. Chakraborty C*, Sharma AR, Sharma G, Lee SS (2020) Therapeutic advances of miRNAs: A preclinical and clinical update. Journal of Advanced Research 28:127-138. doi: 10.1016/j.jare.2020.08.012 IF: 17.1 (Journal Category: Q1) (*First and Corresponding Author)

[https://pubmed.ncbi.nlm.nih.gov/33364050/] (Citation index: 474)

  1. Sharma G, Sharma AR, Bhattacharya M, Lee SS*, Chakraborty C*(2021) CRISPR-Cas9: A preclinical and clinical perspective for the treatment of human diseases. Molecular Therapy 29(2):571-586. doi: 10.1016/j.ymthe.2020.09.028 IF:11.4 (Journal Category: Q1) (*Corresponding Author)

[https://pubmed.ncbi.nlm.nih.gov/33238136/] (Citation index: 359)

  1. Chakraborty C*, Sharma AR, Sharma G, Lee SS (2016) Zebrafish: A complete animal model to enumerate the nanoparticle toxicity. Journal of Nanobiotechnology 14(1):65 IF: 15.0 (Journal Category: Q1) (*First and Corresponding Author)

[https://pubmed.ncbi.nlm.nih.gov/27544212/](Citation index: 400)

  1. Chakraborty C*, Bhattacharya M, Pal S, Lee SS. (2023) From machine learning to deep learning: An advances of the recent data-driven paradigm shift in medicine and healthcare. Current Research in Biotechnology doi: 10.1016/j.crbiot.2023.100164 IF: 6.7 (Journal Category: Q1) (Citation index: 351) (*First and Corresponding Author)
  2. Chakraborty C*, Bhattacharya M, Sharma AR, Mallick B (2022) Omicron (B.1.1.529)- a new heavily mutated variant: mapped location and probable properties of its mutations with an emphasis on S-glycoprotein. International Journal of Biological Macromolecule 219:980-997 doi: 10.1016/j.ijbiomac.2022.07.254 IF: 8.7 (Journal Category: Q1) (*First and Corresponding Author)

[https://pubmed.ncbi.nlm.nih.gov/35952818/] (Citation index: 86)

  1. Chakraborty C*, Sharma AR, Bhattacharya M, Agoramoorthy G, Lee SS (2021) Evolution, Mode of Transmission, and Mutational Landscape of Newly Emerging SARS-CoV-2 Variants. mBio 12(4): e0114021.doi: 10.1128/mBio.01140-21 IF: 5.4 (Journal Category: Q1) (*First and Corresponding Author)

[https://pubmed.ncbi.nlm.nih.gov/34465019/] (Citation index: 86)

[mBio is a is an official journal of the American Society of Microbiology (ASM)]

  1. Bhattacharya M, Sharma AR,Dhama K,Agoramoorthy G,Chakraborty C*(2022) Omicron variant (B.1.1.529) of SARS-CoV-2: Understanding mutations in the genome, S-glycoprotein, and antibody binding regions. GeroScience 44(2):619-637doi:10.1007/s11357-022-00532-4 IF: 6.0 (Journal Category: Q1) (*Co-first and Corresponding Author)

[https://pubmed.ncbi.nlm.nih.gov/35258772/] (Citation index: 75)

[GeroScience is an official journal of the American Aging Association (AGE)]

[ The paper has been selected for the GeroScience Publication Award Honorable Mention twice (2024 and 2025) by the American Aging Association (AGE) and GeroScience].

  1. Doss. CGP, Chakraboty C, Syed Haneef SA, NagaSundaram N, Chen L, Zhu H (2014) Evolution- and structure-based computational strategy reveals the impact of deleterious missense mutations on MODY 2 (maturity-onset diabetes of the young, type 2). Theranostics 4(4):366-385. IF:14.9 (Journal Category: Q1)

[https://pubmed.ncbi.nlm.nih.gov/24578721/] (Citation index: 67)

  1. Chakraborty C*, Sharma AR, Bhattacharya M,Zayed H, Lee SS (2021) Understanding gene expression and transcriptome profiling of COVID-19: An initiative towards the mapping of protective immunity genes against SARS-CoV-2 infection. Frontiers in Immunology 12: 724936.doi:10.3389/fimmu.2021.724936 IF: 7.0 (Journal Category: Q1) (*First and Corresponding Author)

[https://pubmed.ncbi.nlm.nih.gov/34975833/] (Citation index: 32)

  1. 11. Kumar S. Sharma AR, Sharma G, Chakraborty C*, Kim J* (2016) PLK-1: Angel or Devil for cell cycle progression. Biochimica et Biophysica Acta (BBA) – Reviews on Cancer 1865(2):190-203 IF: 11.2 (Journal Category: Q1) (*Corresponding Author)

[https://pubmed.ncbi.nlm.nih.gov/26899266/] (Citation index: 73)

  1. Chakraborty C*, Bhattacharya M, Sharma AR, Dhama K (2022) Evolution, epidemiology, geographical distribution and mutational landscape of newly emerging monkeypox virus. GeroScience doi: 10.1007/s11357-022-00659-4 IF: 6.0 (Journal Category: Q1) (*First and Corresponding Author)

[https://pubmed.ncbi.nlm.nih.gov/36094771/] (Citation index: 50)

[GeroScience is an official journal of the American Aging Association (AGE)]

 

  1. Bhattacharya M, Chatterjee S, Nag S, Dhama K, Chakraborty C*(2022) Designing, characterization, and immune stimulation of a novel multi-epitopic peptide-based potential vaccine candidate against monkeypox virus through screening its whole genome encoded proteins: An immunoinformatics approach. Travel Medicine and Infectious Disease 50:102481doi: 10.1016/j.tmaid.2022.102481IF: 5.6 (Journal Category: Q1) (*Corresponding Author)

[https://pubmed.ncbi.nlm.nih.gov/36265732/](Citation index: 51)

  1. Bhattacharya M, Sharma AR, Ghosh P, Lee SS*, Chakraborty C*(2021) A next-generation vaccine candidate using alternative epitopes to protect against Wuhan and all significant mutant variants of SARS-CoV-2: an Immunoinformatics approach. Aging and Disease 12(8):2173-2195 doi:10.14336/AD.2021.0518 IF: 9.6 (Journal Category: Q1) (*Corresponding Author)

[https://pubmed.ncbi.nlm.nih.gov/34881093/] (Citation index: 32)

[Aging and Disease is an official journal of the International Society on Aging and Disease (ISOAD)]

  1. Sharma G, Sharma AR, Nam JS, GeorgePriya Doss C, Lee SS, Chakraborty C*(2015) Nanoparticle based insulin delivery system: the next generation efficient therapy for Type 1 diabetes. Journal of Nanobiotechnology 13:74 IF: 15.0 (Journal Category: Q1) (*Corresponding Author)

[https://pubmed.ncbi.nlm.nih.gov/26498972/] (Citation index: 250)

  1. Chakraborty C*, Sharma AR, Bhattacharya M, Agoramoorthy G, Lee SS (2022) A paradigm shift in the combination changes of SARS-CoV-2 variants and increased spread of delta variant (B.1.617.2) across the world. Aging and Disease 13(3):927-942doi:10.14336/AD.2021.1117 IF: 9.6 (Journal Category: Q1) (*First and Corresponding Author)

[https://pubmed.ncbi.nlm.nih.gov/35656100/] (Citation index: 19)

[Aging and Disease is an official journal of the International Society on Aging and Disease (ISOAD)]

  1. Sharma G, Chatterjee S, Chakraborty C*, Kim JC* (2023) Advances in nanozymes as a paradigm for viral diagnostics and therapy. Pharmacological Reviews 27: PHARMREV-AR-2022-000719. doi: 10.1124/pharmrev.122.000719. IF: 20.3 (Journal Category: Q1) (Citation index: 23) (*Corresponding Author)

[https://pubmed.ncbi.nlm.nih.gov/36707250/]

  1. Bhattacharya M, Chatterjee S, Dhama K, Lee SS, Chakraborty C* (2023) Antibody evasion associated with the RBD significant mutations in several emerging SARS-CoV-2 variants and its subvariants. Drug Resistance Updates 71:101008. doi: 10.1016/j.drup.2023.101008. IF: 22.0 (Journal Category: Q1) (*Co-first and Corresponding Author)

[https://pubmed.ncbi.nlm.nih.gov/37757651/] (Citation index: 18)

  1. Chakraborty C*, Pal S, Bhattacharya M, Dash S, Lee SS (2023) Overview of Chatbots with special emphasis on artificial intelligence-enabled ChatGPT in medical science. Frontiers in Artificial Intelligence doi: 10.3389/frai.2023.1237704 IF: 6.7 (Journal Category: Q1) (*First and Corresponding Author)

[https://pubmed.ncbi.nlm.nih.gov/38028668/] (Citation index: 208)

  1. Chakraborty C*, Bhattacharya M, Pal S, Chatterjee S, Das A, Lee SS (2025) AI-enabled language models (LMs) to large language models (LLMs) and multimodal large language models (MLLMs) in drug discovery and development. Journal of Advanced Research 12:S2090-1232(25)00109-2. doi: 10.1016/j.jare.2025.02.011. IF: 17.1 (Journal Category: Q1) (*First and Corresponding Author)

[https://pubmed.ncbi.nlm.nih.gov/39952319/] (Citation index: 51)

  1. Karthick V, Nagasundaram N, Doss CG, Chakraborty C, Siva R, Lu A, Zhang G, Zhu H. (2016) Virtual screening of the inhibitors targeting at the viral protein 40 of Ebola virus. Infectious Diseases of Poverty 5:12 IF: 7.4 (Journal Category: Q1)

[https://pubmed.ncbi.nlm.nih.gov/26888469/] (Citation index: 67)

  1. Bhattacharya M, Alshammari A, Alharbi M, Dhama K, Lee SS, Chakraborty C* (2023) A novel mutation-proof, next-generation vaccine to fight against upcoming SARS-CoV-2 variants and subvariants, designed through AI enabled approaches and tools, along with the machine learning based immune simulation: A vaccine breakthrough. International Journal of Biological Macromolecules: 242(Pt 2):124893. doi: 10.1016/j.ijbiomac.2023.124893 IF: 8.7 (Journal Category: Q1) (*Joint-first and Corresponding Author)

[https://pubmed.ncbi.nlm.nih.gov/37207746/] (Citation index: 15)

  1. Chakraborty C, Bhattacharya M, Pal S, Lee SS (2025) Prompt-engineering enabled LLM or MLLM and instigative bioinformatics pave the way to identify and characterize the significant SARS-CoV-2 antibody escape mutations. International Journal of Biological Macromolecules doi: 10.1016/j.ijbiomac.2024.138547 IF: 8.7 (Journal Category: Q1) (*First and Corresponding Author)

[https://pubmed.ncbi.nlm.nih.gov/39657873/] (Citation index: 13)

  1. Das A, Bhattacharya M, Abdelhameed AS, Lee SS, Chakraborty C* (2025) Generative artificial intelligence (GenAI), instigative bioinformatics, and single-cell analysis reveal the Alzheimer’s genetic and immune landscape. Molecular Therapy – Nucleic Acids doi: 10.1016/j.omtn.2025.102546 IF 6.5 (Journal Category: Q1) (*Joint-first and Corresponding Author) (Citation index: 4)

 [Molecular Therapy – Nucleic Acids is an official journal of the American Society of Gene & Cell Therapy and a Cell Press Journal]

  1. Sharma AR, Sharma G, Lee SS*, Chakraborty C* (2016) miRNA regulated key components of cytokine signaling pathways and inflammation in rheumatoid arthritis. Medicinal Research Reviews 36(3):425-39. IF: 13.6 (Journal Category: Q1) (*Corresponding Author)

[https://pubmed.ncbi.nlm.nih.gov/26786912/] (Citation index: 88)

  1. Sharma AR, Lee YH, Bhattacharya M, Chakraborty C, Lee SS (2022) Recent advances of metal-based nanoparticles in Nucleic acid delivery for therapeutic applications. Journal of Nanobiotechnology 20(1): 501.doi: 10.1186/s12951-022-01650-z. IF: 15.0 (Journal Category: Q1)

[https://pubmed.ncbi.nlm.nih.gov/36434667/] (Citation index: 116)

SELECTED PUBLICATIONS FROM COLLABORATIVE RESEARCH (SCI/SCIE/ ESCI PUBLICATIONS)

  1. GBD 2021 Risk Factors Collaborators. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 403(10440):2162-2203. doi: 10.1016/S0140-6736(24)00933-4. IF:109 (Journal Category: Q1)

[I am one of the lead authors and members of GBD 2021 Risk Factors Collaborators]

[https://pubmed.ncbi.nlm.nih.gov/38762324/]

  1. GBD 2021 Adult BMI Collaborators. (2025) Global, regional, and national prevalence of adult overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021. Lancet 405(10481):813-838. doi: 10.1016/S0140-6736(25)00355-1. Epub 2025 Mar 3. PMID: 40049186. IF: 109 (Journal Category: Q1)

[I am one of the lead authors and members of GBD 2021 Adult BMI Collaborators]

[https://pubmed.ncbi.nlm.nih.gov/40049186/]

  1. GBD 2021 Forecasting Collaborators. (2024) Burden of disease scenarios for 204 countries and territories, 2022-2050: a forecasting analysis for the Global Burden of Disease Study 2021. Lancet 403(10440):2204-2256. doi: 10.1016/S0140-6736(24)00685-8 IF: 109 (Journal Category: Q1)

[I am one of the lead authors and members of GBD 2021 Forecasting Collaborators]

[https://pubmed.ncbi.nlm.nih.gov/38762325/]

  1. GBD 2021 Causes of Death Collaborators. (2024) Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 403(10440):2100-2132. doi:9.1016/S0140-6736(24)00367-2. IF: 109

[I am one of the lead authors and members of GBD 2021 Causes of Death Collaborators]

[https://pubmed.ncbi.nlm.nih.gov/38582094/]

  1. GBD 2021 Demographics Collaborators. (2024) Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950-2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021. Lancet S0140-6736(24)00476-8. doi: 10.1016/S0140-6736(24)00476-8. IF: 109 (Journal Category: Q1)

[I am one of the lead authors and members of GBD 2021 Demographics Collaborators]

[https://pubmed.ncbi.nlm.nih.gov/38484753/]

  1. GBD 2021 Adolescent BMI Collaborators. (2025) Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021. Lancet 2025 Mar 8;405(10481):785-812. doi: 10.1016/S0140-6736(25)00397-6. IF: 109 (Journal Category: Q1)

[I am one of the lead authors and members of GBD 2021 Adolescent BMI Collaborators]

[https://pubmed.ncbi.nlm.nih.gov/40049185/]

  1. GBD 2021 Fertility and Forecasting Collaborators. (2024) Global fertility in 204 countries and territories, 1950–2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021. Lancet S0140-6736(24)00550-6. doi: 10.1016/S0140-6736(24)00550-6. IF: 109 (Journal Category: Q1)

[I am one of the lead authors and members of GBD 2021 Fertility and Forecasting Collaborators]

[https://pubmed.ncbi.nlm.nih.gov/38521087/]

  1. GBD 2023 Causes of Death Collaborators (2025) Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet S0140-6736(25)01917-8. doi: 10.1016/S0140-6736(25)01917-8. IF: 109 (Journal Category: Q1)

[I am one of the lead authors and members of GBD 2023 Causes of Death Collaborators]

[https://pubmed.ncbi.nlm.nih.gov/41092928/]

  1. GBD 2023 Disease and Injury and Risk Factor Collaborators (2025) Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet S0140-6736(25)01637-X. doi: 10.1016/S0140-6736(25)01637-X. IF: 109 (Journal Category: Q1)

[I am one of the lead authors and members of GBD 2023 Disease and Injury and Risk Factor Collaborators]

[https://pubmed.ncbi.nlm.nih.gov/41092926/]

  1. GBD 2023 Cancer Collaborators (2025) The global, regional, and national burden of cancer, 1990–2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023. Lancet doi: 10.1016/S0140-6736(25)01635-6. IF: 109 (Journal Category: Q1)

[I am one of the lead authors and members of GBD 2023 Cancer Collaborators.]

[https://pubmed.ncbi.nlm.nih.gov/41015051/]

  1. GBD 2023 Vaccine Coverage Collaborators. (2025) Global, regional, and national trends in routine childhood vaccination coverage from 1980 to 2023 with forecasts to 2030: a systematic analysis for the Global Burden of Disease Study 2023. Lancet S0140-6736(25)01037-2. doi: 10.1016/S0140-6736(25)01037-2. IF: 109 (Journal Category: Q1)

[I am one of the lead authors and members of GBD 2023 Vaccine Coverage Collaborators.]

[https://pubmed.ncbi.nlm.nih.gov/40578370/]

  1. GBD 2023 Demographics Collaborators (2025) Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950-2023: a demographic analysis for the Global Burden of Disease Study 2023. Lancet. S0140-6736(25)01330-3. doi: 10.1016/S0140-6736(25)01330-3. IF: 109 (Journal Category: Q1)

[I am one of the lead authors and members of GBD 2023 Demographics Collaborators]

[https://pubmed.ncbi.nlm.nih.gov/41092927/]

  1. GBD 2023 Childhood Cancer Collaborators (2026) Global burden of cancer in children and adolescents aged 0-19 years, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet. 407(10536):1360-1373. doi: 10.1016/S0140-6736(26)00200-X. PMID: 41936367. IF: 109 (Journal Category: Q1)

[I am one of the lead authors and members of GBD 2023 Childhood Cancer Collaborators]

[https://pubmed.ncbi.nlm.nih.gov/41936367/]

  1. GBD 2021 Dietary Iron Deficiency Collaborators (2025) Global, regional and national burden of dietary iron deficiency from 1990 to 2021: a Global Burden of Disease study. Nature Medicine doi: 10.1038/s41591-025-03624-8. IF 52.5 (Journal Category: Q1)

[I am one of the lead authors and members of GBD 2021 Dietary Iron Deficiency Collaborators]

[https://pubmed.ncbi.nlm.nih.gov/40263631/]

  1. GBD 2023 Substance Use Collaborators (2026) Global burden of amphetamine, cannabis, cocaine and opioid use in 204 countries, 1990-2023: a Global Burden of Disease Study. Nature Medicine doi: 10.1038/s41591-025-04137-0. IF 52.5 (Journal Category: Q1)

[I am one of the lead authors and members of GBD 2023 Substance Use Collaborators Collaborators]

[https://pubmed.ncbi.nlm.nih.gov/41545593/]

  1. GBD 2023 Global Chronic Respiratory Disease and COVID Collaborators; Hay SI, Il Shin J, Yon DK. (2026) Global, regional, and national burden of chronic respiratory diseases and impact of the COVID-19 pandemic, 1990-2023: a Global Burden of Disease study. Nature Medicine doi: 10.1038/s41591-025-04077-9. IF 52.5 (Journal Category: Q1)

[https://pubmed.ncbi.nlm.nih.gov/41495401/]

[I am one of the lead authors and Global Chronic Respiratory Disease and Covid Collaborators]

  1. GBD 2021 Stroke Risk Factor Collaborators (2024) Global, regional, and national burden of stroke and its risk factors, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet Neurology 23(10) 973-1003. IF: 54.6 (Journal Category: Q1)

[I am one of the lead authors and members of GBD 2021 Stroke Risk Factor Collaborators]

[https://pubmed.ncbi.nlm.nih.gov/39304265/]

  1. GBD 2021 Diarrheal Diseases Collaborators (2025) Global, regional, and national age-sex-specific burden of diarrheal diseases, their risk factors, and aetiologies, 1990–2021, for 204 countries and territories: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet Infectious Diseases. doi: 10.1016/S1473-3099(24)00691-1. IF: 29.4 (Journal Category: Q1)

[I am one of the lead authors and members of GBD 2021 Diarrheal Diseases Collaborators]

[https://pubmed.ncbi.nlm.nih.gov/39708822/]

  1. GBD 2021 HIV Collaborators (2024) Global, regional, and national burden of HIV/AIDS, 1990-2021, and forecasts to 2050, for 204 countries and territories: the Global Burden of Disease Study 2021. Lancet HIV S2352-3018(24)00212-1 IF: 14.6 (Journal Category: Q1)

[I am one of the lead authors and members of GBD 2021 HIV Collaborators]

[https://pubmed.ncbi.nlm.nih.gov/39608393/]

  1. GBD 2021 Global Sepsis Collaborators (2025) Global, regional, and national sepsis incidence and mortality, 1990–2021: a systematic analysis. The Lancet Global Health doi: 10.1016/S2214-109X (25)00356-0. IF: 22.5 (Journal Category: Q1)

[I am one of the lead authors and members of GBD 2021 Global Sepsis Collaborators]

[https://pubmed.ncbi.nlm.nih.gov/41135560/]

  1. GBD 2023 Breast Cancer Collaborators. (2026) Global, regional, and national burden of breast cancer among females, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023. Lancet Oncology 27(3):302-326. doi: 10.1016/S1470-2045(25)00730-2. IF 33.7 (Journal Category: Q1)

[I am one of the lead authors and members of GBD 2023 Asia Chronic Respiratory Disease Collaborators]

[https://pubmed.ncbi.nlm.nih.gov/41785894/]

  1. GBD 2023 Lower Respiratory Infections and Antimicrobial Resistance Collaborators (2026) Global burden of lower respiratory infections and aetiologies, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023. The Lancet Infectious Diseases S1473-3099(25)00689-9. doi: 10.1016/S1473-3099(25)00689-9. IF: 29.4 (Journal Category: Q1)

[I am one of the lead authors and members of GBD 2023 Lower Respiratory Infections and Antimicrobial Resistance Collaborators]

[https://pubmed.ncbi.nlm.nih.gov/41412141/]

Research Patents:

Total patent:23 (International patent 19 and Inational patent 4)

  1. Development method of epitope-based peptide vaccine against SARS-COV-2 virus (South Korea Patent)
  2. A cloud computing system for extended battery life and enhanced performance (South Africa Patent)
  3. Wall Mountable Mini – Integrated Computer for Robotic Machine Learning(Design Patent) (UK Patent)
  4. A method and system for formulating a multi-epitope peptide vaccine against monkeypox virus (South Africa Patent)
  5. Fan-Less Box Computer(Design Patent) (UK Patent)
  6. Sample Handling Robot for PCR Process(Design Patent) (UK Patent)
  7. Sleek Artificial Intelligence Computing USB Stic(Design Patent) (UK Patent)
  8. Genetic Analyzer (Design Patent) (UK Patent)
  9. An Artificially Intelligent Compact Computing Device, System and Method for Next-Generation Vaccine Design (South Africa Patent)
  10. Method of development of multi-epitope peptide-based vaccine composition (South Korea Patent)
  11. Table-top ultrasonic sanitizer (Design Patent) (Indian Patent)
  12. Touch interfaced HBA1C analyser (Design Patent) (Indian Patent)
  13. CRISPR-based food pathogen Detector (Design Patent) (Indian Patent)
  14. Epitope Peptide from SARS-Coronavirus-2 Variants and Vaccine Candidate Compositions for SARS-Coronavirus-2 Variants Comprising the Same (South Korea Patent)
  15. On-Site CRISPR-Food Pathogen Screening Device (Design Patent) (UK Patent)
  16. Compact Wall-Mountable Autoclave (Design Patent) (Indian Patent)
  17. Epitope Peptide from SARS-Coronavirus-2 Variants and Vaccine Candidate Compositions for SARS-Coronavirus-2 Variants Comprising the Same(South Korea Patent)
  18. On-Site CRISPR-Food Pathogen Screening Device (Design Patent) (UK Patent)
  19. AI-enabled network gateway with distributed ledger (Design Patent) (UK Patent)
  20. Laboratory capsule for genetic editing delivery (Design Patent) (UK Patent)
  21. Smart diagnostic and detection device for crop pathogens (Design Patent) (UK Patent)
  22. Automated Agricultural Seedling Health Testing Device (Design Patent) (UK Patent)
  23. High frequency ultrasonic food fermentation sensor device (Design Patent) (UK Patent)

Research Advisor / Supervisor:

  • Doctoral Thesis Advisor / Supervisor: 3 (Awarded); 2 (ongoing)
  • Post Graduate / Graduate Thesis Advisor: 76 (Awarded)

Award/ Academic Recognition/ Major Professional Activity:

  • 2025- GeroScience Publication Award Honorable Mention! Awarding organization: American Aging Association (AGE) and GeroScience (Official Journal of the American Aging Association (AGE)).
  • 2024- Star Scientist Award (2024), Awarding Organization: Adamas University, Kolkata, India.
  • 2024-AAAS Best Scientist Award (2024), Awarding Organization: Academy for Advancement of Agricultural Sciences (AAAS), Kalyani, WB [This special Award was given at the IPS North-Eastern Zonal Meet & AAAS National Conference at College of Agriculture Tripura, Lembucherra, Tripura from September 26-27, 2024. The Award was handed over by His Excellency Hon’ble Governor of Tripura state in India.]          
  • 2024- GeroScience Publication Award Honorable Mention! American Aging Association (AGE) and Geroscience (Official Journal of the American Aging Association (AGE)), USA
  • 2024- Future Leaders Mentorship Fellow, American Society of Microbiology (ASM), USA (2024-2026)
  • 2023-Selected for “Tata Innovation Fellowship” For 2022-2023, Depart of Biotechnology (DBT), Govt. of India
  • 2023-Global Research Excellence Award, IEEE and IAS (IEEE Industry Application Society)
  • 2021- Chancellor Award (The Award is also called Spirit of Adamas University)
  • Hon’ble Chancellor, Adamas University, Kolkata, India,      
  • 2021- Research excellence award, Awarding organization: Adamas University, Kolkata, India
  • 2021- Research Award, Institute for Skeletal Aging & Orthopedic Surgery, Hallym University, College of Medicine, Chucheon, Gangwondo, South Korea (Value: 1 million korean won After Alien Tax)
  •  2020- AEB-IFI National Award for Excellence in Science [ Academy of Environmental Biology, India]
  • 2020-Research Excellence Award, Adamas University, Kolkata, India (December, 2020)
  • 2016- Recipient of EET-CRS 4th Academic Brilliance Awards-2016 For Best Researcher in 2016
  •  2012- Publication Award For 2010 & 2011, Vit University, Vellore, India (Contains Cash Award of 5,000 And A Certificate).
  • 2010- Publication Award, National Sun Yat Sen University, Taiwan (Value USD 1471
    After Alien Tax).
  • 1999-Snahalata Banerjee Gold Medal 1998, Academy of Environmental Biology, India for Adjudicated Best Published Research Award.

Honors

  • My interview was highlighted in an Obituary article entitled “Christian C Patrick” in the highly prestigious journal “The Lancet Infectious Diseases”.

[Bagcchi S. Christian C Patrick. Lancet Infect Dis. 2026 May;26(5):448. doi: 10.1016/S1473-3099(26)00190-8]

  • My interview was highlighted in an Obituary article entitled “Walter Dowdle” in the highly prestigious journal “The Lancet Infectious Diseases”.

[Bagcchi S. Walter Dowdle. Lancet Infect Dis. 2026 Feb;26(2):124. doi: 10.1016/S1473-3099(26)00011-3.]

[https://pubmed.ncbi.nlm.nih.gov/41619742/]

  • My interview was highlighted in a news article entitled “Progress in global tobacco control measures” in the highly prestigious journal “The Lancet Oncology”.

[Das M. Progress in global tobacco control measures. The Lancet Oncology 2025 DOI: DOI: 10.1016/S1470-2045(25)00755-7]

[Ioannidis, John P.A. (2025), “August 2025 data-update for “Updated science-wide author databases of standardized citation indicators””, Elsevier Data Repository, V8, doi: 10.17632/btchxktzyw.8]

  • My interview was highlighted in a news article entitled “Spanish Government approves proposed tobacco law” in the highly prestigious journal “The Lancet Oncology”.

[Das M. Spanish Government approves proposed tobacco law. The Lancet Oncology 2025 DOI: 10.1016/S1470-2045(25)00556-X]

  • My interview was highlighted in an Obituary article entitled “George Louis Drusano” in the highly prestigious journal “The Lancet Infectious Diseases”.

[Bagcchi S. Martin Danis. Lancet Infect Dis. 2025 25(9):961]

  • My interview was highlighted in an Obituary article entitled “Martin Danis” the highly prestigious journal “The Lancet Infectious Diseases”.

[Bagcchi S. Martin Danis. Lancet Infect Dis. 2025 25(6):611]

  • My interview was highlighted in a news article entitled “Agreements to provide affordable lenacapavir” the highly prestigious journal “The Lancet Microbe”.

[Bagcchi S. Agreements to provide affordable lenacapavir. The Lancet Microbe doi: 10.1016/j.lanmic.2025.101317 -5.]

  • My interview was highlighted in an Obituary article entitled “Ana Gligić” the highly prestigious journal “The Lancet Infectious Diseases”.

[Bagcchi S. Ana Gligić. Lancet Infect Dis. 2025 25(3):259. doi: 10.1016/S1473-3099(25)00094-5. PMID: 40023190]

[https://pubmed.ncbi.nlm.nih.gov/40023190/]

  • Keynote talk at IUBMB (In AI in biomedical research: IUBMB Trainee Initiative webinar on April 27th, 2024. by International Union of Biochemistry and Molecular Biology (IUBMB). (Date of presentation: April 27th, 2024, 2024. (at 1pm GMT).)Trainee Initiative was highlighted in two different documents, which are as follows:

IUBMB newsletter 2024 (Page 11) and highly prestigious journal “Trends in Biochemical Sciences (Cell press Journal)”

[Cozma E, Penndorf P. IUBMB Trainee Initiative: supporting emerging biochemists and molecular biologists worldwide. Trends Biochem Sci. 2024 Sep;49(9):749-751. doi: 10.1016/j.tibs.2024.07.004. PMID: 39241748]

[Ioannidis, John P.A. (2024), “August 2024 data-update for “Updated science-wide author databases of standardized citation indicators””, Elsevier Data Repository, V7, doi: 10.17632/btchxktzyw.7]

  • My interview was highlighted in an Obituary article entitled “Phyllis Dako-Gyeke” the journal “The Lancet Infectious Diseases”.

[Bagcchi S. Phyllis Dako-Gyeke. Lancet Infect Dis. 2024 Sep;24(9):950. doi: 10.1016/S1473-3099(24)00517-6. PMID: 39181136.]

[https://pubmed.ncbi.nlm.nih.gov/39181136/]

  • My interview was highlighted in an Obituary article entitled “Kenneth Ira Berns” the journal “The Lancet Infectious Diseases”.

[Bagcchi S. Kenneth Ira Berns. Lancet Infect Dis. 2024 Jun;24(6):576. doi: 10.1016/S1473-3099(24)00303-7. PMID: 38795723]

[https://pubmed.ncbi.nlm.nih.gov/38795723/]

  • My interview was highlighted in a news article entitled “UNICEF report reveals gender gaps persist in HIV.” in the journal “The Lancet Infectious Diseases”.

[Das M. UNICEF report reveals gender gaps persist in HIV. Lancet Infect Dis. 2024 Mar;24(3):e159. doi: 10.1016/S1473-3099(24)00092-6. PMID: 38401563.]

[https://pubmed.ncbi.nlm.nih.gov/38401563/]

  • My interview was highlighted in a news article entitled “Laos eliminates lymphatic filariasis” in the journal “The Lancet Infectious Diseases.”

[Bagcchi S. Laos eliminates lymphatic filariasis. Lancet Infect Dis. 2024 Jan;24(1):e17. doi: 10.1016/S1473-3099(23)00770-3. PMID: 38141647.]

[https://pubmed.ncbi.nlm.nih.gov/38141647/]

[https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00770-3/fulltext]

  • My interview was highlighted in a news article entitled “DNDi receives Dutch funding boost” in the journal “The Lancet Infectious Diseases”

[Bagcchi S. DNDi receives Dutch funding boost. Lancet Infect Dis. 2023 May;23(5):535. doi: 10.1016/S1473-3099(23)00222-0. PMID: 37086729.]

[https://pubmed.ncbi.nlm.nih.gov/37086729/]

[Ioannidis, John P.A. (2023), “October 2023 data-update for “Updated science-wide author databases of standardized citation indicators””, Elsevier Data Repository, V6, doi: 10.17632/btchxktzyw.6]

[Ioannidis, John P.A. (2022), “September 2022 data-update for “Updated science-wide author databases of standardized citation indicators””, Elsevier Data Repository, V5, doi: 10.17632/btchxktzyw.5]

[Baas, Jeroen; Boyack, Kevin; Ioannidis, John P.A. (2021), “August 2021 data-update for “Updated science-wide author databases of standardized citation indicators””, Elsevier Data Repository, V3, doi: 10.17632/btchxktzyw.3

[Baas, Jeroen; Boyack, Kevin; Ioannidis, John P.A. (2020), “Data for “Updated science-wide author databases of standardized citation indicators””, Elsevier Data Repository, V2, doi: 10.17632/btchxktzyw.2 and

Ioannidis et al. Updated science-wide author databases of standardized citation indicators. PLoS Biol. 2020 18(10):e3000918. PMID: 33064726)]